• 1
    Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF. Dermatology in General Medicine. New York : McGraw Hill Inc, 1993.
  • 2
    Mowsowicz I, Riahi M, Wright F, Bouchard F, Kutten F, Mauvais-Jarvis P. Androgen receptor in human skin cytosol. J Clin Endocrinol Metab 1981; 52: 338344.
  • 3
    Brown TR, Migeon CJ. Cultured human skin fibroblasts: a methodfor the study of androgen action. Mol Cell Biochem 1981; 36: 322.
  • 4
    Ruizveld de Winter, JA, Trapmann J, Vermey M, Mulder E, Zegers ND, Van der Kwast TH. Androgen receptor expression in human tissues: an immunohistochemical study. J Histochem Cytochem 1991; 39: 927936.
  • 5
    Choudhry R, Hodgins MB, Van der Kwast TH, Brinkmann AO, Boersma WJA. Localization of androgen receptors in human skin byimmunohistochemistry: implications for the hormonal control of hairgrowth, sebaceous glands and sweat glands. J Endocrinol 1992; 133:467475.
  • 6
    Blauer M, Vaalasti A, Pauli SL, Ylikomi T, Joensuu T, Tuohimaa P. Location of androgen receptor in human skin. J Invest Dermatoll 1997; 97: 264268.
  • 7
    Liang T, Hoyer S, YuR et al. Immunocytochemical localization ofandrogen receptors in human skin using monoclonal antibodiesagainst the androgen receptor. J Invest Dermatol 1993; 100: 663666.
  • 8
    Itami S, Kurata S, Sonoda T, Takayasu S. Interaction between dermalpapilla cells and follicular epithelial cells in vitro: effect of androgen. Br J Dermatol 1995; 132: 527532.
  • 9
    Stumpf WE, Narbaitz R, Sar M. Estrogen receptors in the fetalmouse. J Steroid Biochem 1980; 12: 5564.
  • 10
    Cooke PS, Young P, Hess RA, Cunha GR. Estrogen receptor expres-sion in developing epididymis, efferent ductules, and other malereproductive organs. Endocrinology 1991; 128: 28742879.
  • 11
    Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS. Alterationof reproductive function but not prenatal sexual development afterinsertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA 1993; 90: 1116211166.
  • 12
    McLean JM. Anatomy and physiology of the vulval area. In: RidleyCM, editor. The Vulva. London : Churchill Livingstone, 1988.
  • 13
    Maheux R, Naud F, Rioux M et al. A randomized double-blind, placebo-controlled study on the effect of conjugated estrogens on skinthickness. Am J Obstet Gynecol 1994; 170: 642649.
  • 14
    CasteloBranco C, Duran M, Gonzalezmerlo J. Skin collagen changesrelated to age and hormone replacement therapy. Maturitas 1992; 15: 113119.
  • 15
    Bartelink ML, DeWit A, Wollersheim H, Theeuwes A, Thien T. Skinvascular reactivity in healthy subjects: influence of hormonal status. J Appl Physiol 1993; 74: 727732.
  • 16
    Friedrich EGJr, Kalra PS. Serum levels of sexhormones in vulvarlichen sclerosus and the effect of topical testosterone. N Eng J Med 1984; 310: 488491.
  • 17
    Friedrich EG. Jr. Vulvar dystrophy. Clin Obstet Gynecol 1985; 28: 178187.
  • 18
    Onnis A, Becagli L. Topical treatment of vulvar dystrophies withprogesterone. Clin Exp Obstet Gynecol 1986; 13: 1517.
  • 19
    Ayhan A, Urman B, Yuce K, Ayhan A, Gokoz A. Topical testosteronefor lichen sclerosus. Int J Gynaecol Obstet 1989; 30: 253255.
  • 20
    Perrot-Applanat M, Groyer-Picard M-T, Lorenzo F et al. Immuno-cytochemical study with monoclonal antibodies to progesteronereceptor in human breast tumors. Cancer Res 1987; 47: 26522661.
  • 21
    Webb P, Lopez GN, Greene GI, Baxter JD, Kushner PJ. The limits ofthe cellular capacity to mediate an estrogen response. Mol Endocrinol 1992; 6 157167.
  • 23
    Vanderbilt JN, Miesfeld R, Maler BA, Yamamoto KR. Intracellularreceptor concentration limits glucocorticoid dependent enhanceractivity. Mol Endocrinol 1987; 1: 6874.
  • 23a
    McClelland RA, Berger U, Miller LS, Powles TJ, Jensen EV, Coombes RC. Immunocytochemical assay for estrogen receptor: rela-tionship to outcome of therapy in patients with advanced breast disease. Cancer Res 1986; 46: 4241s4243s.
  • 24
    Gaskell DJ, Hawkins RA, Sangster L, Chetty U, Forrest APM. Relationship between immunocytochemical estimation of oestrogenreceptor in elderly patients with primary breast cancer and response totamoxifen. Lancet 1989; 1: 10441048.
  • 25
    Moms JM, Mahesh VB. Further observations on the syndrome of ‘testicular feminization’. Am J Obstet Gynecol 1963; 87: 731748.
  • 26
    McKenzie RC, Sauder DN. The role of keratinocyte cytokines ininflammation and immunity. J Invest Dermatol 1990; 95: 105s107s.
  • 27
    Kimbauer R, Kock A, Neuner P et al. Regulation of epidermal cellinterleukin-6 production by UV light and corticosteroids. J Invest Dermatol 1991; 96: 484489.
  • 28
    Carli P, Cattaneo A, Pimpinelli N, Cozza A, Bracco G, GiaMOtti B. Immunohistochemical evidence of skin immune system involvement invulvar lichen sclerosus et atrophicus. Dermatologica 1991; 182: 1822.
  • 29
    Press MF, Nousek Goebel NA, Bur M, Greene GL. Estrogen receptorlocalization in the female genital tract. Am J Pathol 1986; 123:280292.
  • 30
    Nauth HF. Cytologic and histologic observations on the sex hormonedependence of the vulva. J Reprod Med 1985; 30: 667674.
  • 31
    Kalloo NB, Gearhart JP, Barrack ER. Sexually dimorphic expressionof estrogen receptors but not androgen receptors in human fetal exter-nal genitalia. J Clin Endocrinol Metab 1993; 77: 692698.
  • 32
    MacLean AB, Nicol LA, Hodgins MB. lmmunohistochemical local-ization of estrogen receptors in the vulva and vagina. J Reprod Med 1990; 35: 10151016.
  • 33
    Murphy JB, Emmott RC, Hicks IA, Walsh PC. Estrogen receptors inthe human prostate, seminal vesicle, cpididymis, testis and genitalskin: a marker for estrogen sensitive tissues J Clin Endocrinol Metab 1980; 50: 938948.
  • 34
    Hasselquist MB, Goldberg N, Schroeter A, Spelsberg TC. Isolationand characterization of the estrogen receptor in human skin. J Clin Endocrinol Metab 1980; 50: 7682.
  • 35
    Schmidt JB, Lindmaier A, Spona J. Hormone receptors in pubic skinof premenopausal and postmenopausal females. Gynecol Ohstet Invest 1990; 30: 97100.
  • 36
    Omsjo IH, Wright PB, Bormer OP. Estrogen and progesterone recep-tors in normal and malignant vulvar tissue. Gynecol Ohstet Invest 1984; 17: 281283.
  • 37
    Garau JM, DiPaola GR, Charreau EH. Estrogen and progesteronereceptor assays on the vulvar epithelium. J Reprod Med 1986; 31: 987991.
  • 38
    Ciocca DR, Vargas Roig LM. Estrogen receptors in human nontargettissues: biological and clinical implications. Endocrine Rev 1995; 16:3562.
  • 39
    Mikkola T, Turunen P, Avela K, Orpana A, Viinikka L, Ylikorkala O. 17β-oestradiol stimulates prostacyclin but not endothelin- 1 produc-tion in human vascular endothelial cells. J Clin Endocrinol Metab 1995; 80: 18321836.
  • 40
    Sawers RS, Randall VA, Ebling FJG. Control of hidradenitis suppura-tiva in women using combined antiandrogen (cyproterone acetate)and estrogen therapy. Br J Deriatol 1986; 115: 269274.
  • 41
    Mortimer PS, Dawber RPR, Gales MA, Moore RA. A double blindcontrolled crossover trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol 1986; 115: 263268.
  • 42
    Bellido T, Jilka RL, Boree BF, Girasole G et al. Regulation of inter-leukin-6 osteoclastogenesis and bone mass by androgens. The role ofthc androgen receptor. J Clin Invest 1995; 95: 28862895.
  • 43
    Pottratz S, Bellido T, Mocharla H, Crabb D, Manologas SC. 17β-oestradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor dependent mechanism. J Clin Invest 1994; 93: 944950.